HOUSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/celltherapy?src=hash" target="_blank"gt;#celltherapylt;/agt;–SpinalCyte, LLC, a Texas-based regenerative medicine company focused on
regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today
announced that Pete O’Heeron, SpinalCyte’s Chief Executive Officer, will
present at the China Focus @ Europe Vienna on Wednesday, March 27, 2019
at 3:00 PM CET in Vienna, Austria.
In his presentation, Mr. O’Heeron will discuss SpinalCyte’s global focus
and provide a clinical and business update on SpinalCyte’s
fibroblast-based cell therapy technology, CybroCell™. SpinalCyte holds
two issued Chinese patents and three Chinese patents pending covering
its fibroblast cell therapy technologies. Data from the Phase I/II
CybroCell™ study demonstrated sustained improvement in pain relief and
disc height beyond the 12-month endpoint. The company is preparing for
continued clinical trials and development after receiving FDA clearance
of its Investigational New Drug protocol.
About China Focus @ Europe
Since the recent reform of China’s drug approval process, clinical
trials and new drug approval in China has accelerated. In the past year,
a record setting 34 pharmaceutical products and five biotech products
were approved. This opened the Chinese market to drug development
companies from around the world and ignited license-in interest from
Chinese public pharmaceutical companies. China Focus @ Europe Vienna is
bringing together investors and pharmaceutical leaders from China along
with international healthcare innovators for an exclusive event designed
to inspire, educate and foster cross-border investment and collaboration
in leading biopharmaceutical innovations from around the world. The
conference will be held on March 27, 2019 at Hilton Vienna Danube
Waterfront Vienna, Austria.
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s
spinal disc breaks down and can begin to collapse. It is estimated that
85% of people over the age of 50 have evidence of disc degeneration and
over 1.3 million procedures a year are performed to treat the disease.
The most common treatments for patients with DDD are either discectomy
or spinal fusion. Discectomy is the partial or full removal of the
degenerated disc to decompress and relieve the nervous system but can
cause long term pain. In a spinal fusion procedure, the entire disc is
removed and the two adjacent vertebrae are fused together. It often
increases strain on the adjacent discs and surrounding tissues leading
to further degeneration.
About CybroCell™
CybroCell™ is the first off-the-shelf allogenic human dermal fibroblast
(HDF) product for the treatment of degenerative disc disease.
SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal
fibroblasts in the treatment of DDD demonstrated sustained improvement
in pain relief and mobility beyond the 12-month endpoint.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine
company developing an innovative solution for spinal disc regeneration
using human dermal fibroblasts. Currently, SpinalCyte holds 39 U.S. and
international issued patents and has filed for an additional 100+
patents across a variety of disease pathways, including disc
degeneration, cancer, diabetes, liver failure and heart failure. Funded
entirely by angel investors, SpinalCyte represents the next generation
of medical advancement in cell therapy. Visit www.spinalcyte.com.
Contacts
David Schull or Ned Berkowitz
Russo Partners LLC
858-717-2310
646-942-5629
david.schull@russopartnersllc.com
ned.berkowitz@russopartnersllc.com
Clinical
Contact:
info@spinalcyte.com